Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yasushi Fukuda

Showing results (21-30 of 37) with videos related to

Pageof 4
Sort By:
BMC Cancer|February 5, 2020
Prediction of patients with a tumor proportion score > 50% who do not respond to first-line monotherapy with pembrolizumabMitsunori Morita, Motohiro Tamiya, Daichi Fujimoto, et al.
Lung Cancer (Amsterdam, Netherlands)|July 21, 2022
Prospective multicenter cohort study of durvalumab for patients with unresectable stage III non-small cell lung cancer and grade 1 radiation pneumonitisTakeya Sugimoto, Daichi Fujimoto, Yuki Sato, et al.
Lung Cancer (Amsterdam, Netherlands)|August 27, 2025
Impact of B7-H3 and DLL3 expression on the efficacy of PD-L1 blockade therapy in extensive-stage small cell lung cancerTakashi Kurosaki, Hiroaki Kanemura, Tomoyuki Otani, et al.
Investigational New Drugs|January 6, 2021
Durvalumab for patients with unresectable stage III non-small cell lung cancer and grade 1 radiation pneumonitis following concurrent chemoradiotherapy: a multicenter prospective cohort studyTakeya Sugimoto, Daichi Fujimoto, Yuki Sato, et al.
Medical Oncology (Northwood, London, England)|June 30, 2025
Phase II study of carboplatin + weekly paclitaxel for advanced lung squamous cell carcinoma with idiopathic interstitial pneumonia (Hanshin Cancer Group IP001)Hidekazu Suzuki, Akito Hata, Takaaki Tokito, et al.
JTO Clinical and Research Reports|February 26, 2025
Pembrolizumab and Pemetrexed for Older Patients With Nonsquamous NSCLC and Programmed Cell Death-Ligand 1 Tumor Proportion Scores of Less Than 50Yoshihito Kogure, Hiroya Hashimoto, Haruko Daga, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 16, 2020
Impact of EGFR-TKI Treatment on the Tumor Immune Microenvironment in <i>EGFR</i> Mutation-Positive Non-Small Cell Lung CancerKohsuke Isomoto, Koji Haratani, Hidetoshi Hayashi, et al.
Internal Medicine (Tokyo, Japan)|November 17, 2015
Composite Physiologic Index, Percent Forced Vital Capacity and Percent Diffusing Capacity for Carbon Monoxide Could Be Predictors of Pirfenidone Tolerability in Patients with Idiopathic Pulmonary FibrosisSatoshi Konishi, Machiko Arita, Isao Ito, et al.
Investigational New Drugs|August 9, 2019
Efficacy and safety of pembrolizumab as first-line therapy in advanced non-small cell lung cancer with at least 50% PD-L1 positivity: a multicenter retrospective cohort study (HOPE-001)Motohiro Tamiya, Akihiro Tamiya, Kazutaka Hosoya, et al.
Investigational New Drugs|January 28, 2022
Classification and regression tree for estimating predictive markers to detect T790M mutations after acquired resistance to first line EGFR-TKI: HOPE-002Motohiro Tamiya, Kei Fujikawa, Hidekazu Suzuki, et al.
Pageof 4

Showing results (21-30 of 37) with videos related to

Sort By:
Pageof 4
BMC Cancer|February 5, 2020
Prediction of patients with a tumor proportion score > 50% who do not respond to first-line monotherapy with pembrolizumabMitsunori Morita, Motohiro Tamiya, Daichi Fujimoto, et al.
Lung Cancer (Amsterdam, Netherlands)|July 21, 2022
Prospective multicenter cohort study of durvalumab for patients with unresectable stage III non-small cell lung cancer and grade 1 radiation pneumonitisTakeya Sugimoto, Daichi Fujimoto, Yuki Sato, et al.
Lung Cancer (Amsterdam, Netherlands)|August 27, 2025
Impact of B7-H3 and DLL3 expression on the efficacy of PD-L1 blockade therapy in extensive-stage small cell lung cancerTakashi Kurosaki, Hiroaki Kanemura, Tomoyuki Otani, et al.
Investigational New Drugs|January 6, 2021
Durvalumab for patients with unresectable stage III non-small cell lung cancer and grade 1 radiation pneumonitis following concurrent chemoradiotherapy: a multicenter prospective cohort studyTakeya Sugimoto, Daichi Fujimoto, Yuki Sato, et al.
Medical Oncology (Northwood, London, England)|June 30, 2025
Phase II study of carboplatin + weekly paclitaxel for advanced lung squamous cell carcinoma with idiopathic interstitial pneumonia (Hanshin Cancer Group IP001)Hidekazu Suzuki, Akito Hata, Takaaki Tokito, et al.
JTO Clinical and Research Reports|February 26, 2025
Pembrolizumab and Pemetrexed for Older Patients With Nonsquamous NSCLC and Programmed Cell Death-Ligand 1 Tumor Proportion Scores of Less Than 50Yoshihito Kogure, Hiroya Hashimoto, Haruko Daga, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 16, 2020
Impact of EGFR-TKI Treatment on the Tumor Immune Microenvironment in <i>EGFR</i> Mutation-Positive Non-Small Cell Lung CancerKohsuke Isomoto, Koji Haratani, Hidetoshi Hayashi, et al.
Internal Medicine (Tokyo, Japan)|November 17, 2015
Composite Physiologic Index, Percent Forced Vital Capacity and Percent Diffusing Capacity for Carbon Monoxide Could Be Predictors of Pirfenidone Tolerability in Patients with Idiopathic Pulmonary FibrosisSatoshi Konishi, Machiko Arita, Isao Ito, et al.
Investigational New Drugs|August 9, 2019
Efficacy and safety of pembrolizumab as first-line therapy in advanced non-small cell lung cancer with at least 50% PD-L1 positivity: a multicenter retrospective cohort study (HOPE-001)Motohiro Tamiya, Akihiro Tamiya, Kazutaka Hosoya, et al.
Investigational New Drugs|January 28, 2022
Classification and regression tree for estimating predictive markers to detect T790M mutations after acquired resistance to first line EGFR-TKI: HOPE-002Motohiro Tamiya, Kei Fujikawa, Hidekazu Suzuki, et al.
Pageof 4